Nelson Research Gets Agreement for Skin Patch : Nichols Institute Takes Steps to Acquire Lab After more than two years of testing, Schering-Plough Corp. has exercised its option to enter into an exclusive, multi-national license agreement with Irvine's Nelson Research & Development Co. for the development and marketing of a bandage-type patch that delivers medicine through the skin, Eric L. Nelson, chairman and president of the R&D firm, said Thursday. and The as yet unnamed product will use Nelson's patented Tranzone patch,
which delivers drugs continuously through the skin without a needle, and the company's proprietary agent, Azone, which enhances penetration of the skin. and Nelson would not reveal what drugs or what purposes Schering-Plough
would use the patch for. A patch is similar to the tiny bandage put behind the ear to deliver anti-sea-sickness medicine through the skin. Some heart patients also use patches to deliver nitroglycerine through the skin and into the blood system. and The product that Schering-Plough plans to market will likely produce
sales of $50 million a year, Nelson said. His company's income will be in the form of royalties on sales "in the 5% to 10% range," he said. and Nelson R&D designs and develops pharmaceutical products, particularly
drug receptor technology, for license.